178 related articles for article (PubMed ID: 34946232)
1. Self-Administration of Long-Acting Somatostatin Analogues in NET Patients-Does It Affect the Clinical Outcome?
Sowa-Staszczak A; Opalińska M; Kurzyńska A; Morawiec-Sławek K; Gilis-Januszewska A; Palen-Tytko J; Olearska H; Hubalewska-Dydejczyk A
Medicina (Kaunas); 2021 Nov; 57(12):. PubMed ID: 34946232
[No Abstract] [Full Text] [Related]
2. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
Enzler T; Fojo T
Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
[TBL] [Abstract][Full Text] [Related]
3. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
Jimenez-Fonseca P; Carmona-Bayonas A; Lamarca A; Barriuso J; Castaño A; Benavent M; Alonso V; Riesco MDC; Alonso-Gordoa T; Custodio A; Sanchez Canovas M; Hernando J; López C; La Casta A; Fernandez Montes A; Marazuela M; Crespo G; Diaz JA; Feliciangeli E; Gallego J; Llanos M; Segura A; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle J; Garcia-Carbonero R
Neuroendocrinology; 2022; 112(1):88-100. PubMed ID: 33508849
[TBL] [Abstract][Full Text] [Related]
4. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO).
Adelman D; Truong Thanh XM; Feuilly M; Houchard A; Cella D
Adv Ther; 2020 Apr; 37(4):1608-1619. PubMed ID: 32157626
[TBL] [Abstract][Full Text] [Related]
6. An international simulated-use study to assess nurses' preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3).
Ferone D; Martin W; Williams J; Houchard A; Pommie C; Ribeiro-Oliveira A; Grossman AB
J Endocrinol Invest; 2024 Feb; 47(2):421-432. PubMed ID: 37550552
[TBL] [Abstract][Full Text] [Related]
7. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients.
van Thiel SW; Romijn JA; Biermasz NR; Ballieux BE; Frölich M; Smit JW; Corssmit EP; Roelfsema F; Pereira AM
Eur J Endocrinol; 2004 Apr; 150(4):489-95. PubMed ID: 15080778
[TBL] [Abstract][Full Text] [Related]
8. Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET).
Ström T; Kozlovacki G; Myrenfors P; Almquist M
Patient Prefer Adherence; 2019; 13():1799-1807. PubMed ID: 31695341
[TBL] [Abstract][Full Text] [Related]
9. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
[TBL] [Abstract][Full Text] [Related]
11. Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients.
Ni K; Yang JY; Baeg K; Leiter AC; Mhango G; Gallagher EJ; Wisnivesky JP; Kim MK
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1387. PubMed ID: 33835729
[TBL] [Abstract][Full Text] [Related]
12. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
Faggiano A
J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs.
Lenotti E; Alberti A; Spada F; Amoroso V; Maisonneuve P; Grisanti S; Baggi A; Bianchi S; Fazio N; Berruti A
Front Endocrinol (Lausanne); 2021; 12():669484. PubMed ID: 33986731
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
15. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
Rinke A; Maintz C; Müller L; Weber MM; Lahner H; Pavel M; Saeger W; Houchard A; Ungewiss H; Petersenn S
Exp Clin Endocrinol Diabetes; 2021 Jul; 129(7):500-509. PubMed ID: 34293802
[TBL] [Abstract][Full Text] [Related]
16. Long-acting formulations of somatostatin analogues.
Anthony LB
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S216-8. PubMed ID: 10604134
[TBL] [Abstract][Full Text] [Related]
17. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.
Ryan P; McBride A; Ray D; Pulgar S; Ramirez RA; Elquza E; Favaro JP; Dranitsaris G
J Oncol Pharm Pract; 2019 Sep; 25(6):1425-1433. PubMed ID: 30924737
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K; Lamberts SW
Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
[TBL] [Abstract][Full Text] [Related]
19. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
Jenkins PJ; Akker S; Chew SL; Besser GM; Monson JP; Grossman AB
Clin Endocrinol (Oxf); 2000 Dec; 53(6):719-24. PubMed ID: 11155094
[TBL] [Abstract][Full Text] [Related]
20. The safety of lanreotide for neuroendocrine tumor.
Godara A; Siddiqui NS; Byrne MM; Saif MW
Expert Opin Drug Saf; 2019 Jan; 18(1):1-10. PubMed ID: 30582380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
